ArticleDiscover oncology2026
Clinicopathological features and survival outcomes of patients with different distant and lymph node metastasis in pancreatic cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPancreatic cancer is a highly lethal malignancy, usually diagnosed when metastasis is present. Detailed analysis of distant (DM) and lymph node (LN) metastasis patterns is crucial for prognosis. This study evaluated metastasis-specific prognosis in pancreatic cancer patients from 2010 to 2016 and developed a validated nomogram for survival prediction.
methodsData of patients with metastatic pancreatic cancer who received chemotherapy or radiotherapy were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Pearson’s chi-square test was utilized to analyze clinicopathological variables. Kaplan–Meier survival analysis and log-rank tests were employed to evaluate overall survival and prognostic outcomes. A nomogram for prognosis prediction was constructed using univariate and multivariate analyses, combined with the Cox proportional hazards regression model.
resultsDistant metastasis (DM) most commonly occurred in the liver (44.8%), followed by the bone (9.5%). Approximately 63.2% of patients had single-site metastasis, whereas 26.0% had metastases in two distant organs. Regional lymph node (LN) involvement was observed in 14.3% of pancreatic cancer patients, among whom only 3.7% concurrently had DM, with the liver being the most frequently involved organ, in which the liver was the most common organ. At the end of the follow-up period 152 patients in 1805 were alive. For pancreatic carcinoma patients with DM the median survival decreased to 4.0 months, while with LN that was 31.05 months. The nomogram was proven to be acceptable consistency in train and validation sets, and the c-index was 0.763.
conclusionWe conducted a comparative analysis of clinicopathological characteristics and clinical outcomes among cases of metastatic pancreatic cancer. Furthermore, we developed a prognostic nomogram that demonstrated excellent performance in both the training and validation cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.